Share This Page
Drug Price Trends for SM CHLD PAIN-FEVER
✉ Email this page to a colleague
Average Pharmacy Cost for SM CHLD PAIN-FEVER
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SM CHLD PAIN-FEVER 160 MG/5 ML | 49348-0093-34 | 0.01931 | ML | 2025-09-17 |
| SM CHLD PAIN-FEVER 160 MG/5 ML | 49348-0119-34 | 0.01931 | ML | 2025-09-17 |
| SM CHLD PAIN-FEVER 160 MG/5 ML | 49348-0119-34 | 0.01921 | ML | 2025-08-20 |
| SM CHLD PAIN-FEVER 160 MG/5 ML | 49348-0093-34 | 0.01921 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for SM CHLD PAIN-FEVER
What is SM CHLD PAIN-FEVER?
SM CHLD PAIN-FEVER is a proprietary pediatric analgesic and antipyretic medication indicated for managing pain and fever in children. Its active ingredients typically include paracetamol (acetaminophen) or ibuprofen, combined with excipients following pediatric dosing guidelines. It is prescribed for children aged 2-12 years, with formulations in syrups, suspensions, or chewable tablets.
Current Market Landscape
Industry Scope
The pediatric analgesic market globally was valued at approximately USD 4.3 billion in 2022, with an expected Compound Annual Growth Rate (CAGR) of 4.2% through 2028. Growth is driven by increasing awareness of pediatric health, expanding vaccination programs, and rising prevalence of minor ailments like fever and pain.
Competitive Environment
Leading brands include:
- Tylenol (Johnson & Johnson)
- Advil (Pfizer)
- Children's Motrin (Johnson & Johnson)
- Store brands (Walgreens, CVS)
Market share distribution is:
- Tylenol: 40%
- Children's Motrin: 25%
- Store brands: 20%
- Other brands: 15%
Regulatory Status
The U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global regulators approve pediatric formulations. Regulatory approval typically requires demonstrating safety, efficacy, and quality in pediatric populations.
Patent and Exclusivity Opportunities
Few patents are active for pediatric formulations of paracetamol or ibuprofen, as most have expired. New formulations or delivery mechanisms, such as dissolvable tablets or extended-release suspensions, may attract patent protections lasting 10-15 years.
Market Entry Considerations for SM CHLD PAIN-FEVER
- Regulatory pathway: Priority review for pediatric medications.
- Market differentiation: Innovative delivery (e.g., flavoring, packaging).
- Pricing strategy: Premium pricing possible with perceived quality; competitive pricing to increase volume.
- Distribution channels: Pharmacies, pediatric clinics, hospitals.
Price Projections
Current Pricing
| Formulation | Avg. Retail Price (USD) (per 100 ml/10 tablets) | Market Share (%) |
|---|---|---|
| Paracetamol suspensions | 4.50 | 55% |
| Ibuprofen suspensions | 5.00 | 30% |
| Chewable tablets | 6.00 | 15% |
Projected Pricing (Next 5 Years)
| Scenario | Approximate Price Range (USD) | Assumptions |
|---|---|---|
| Conservative | $4.50 - $6.00 | Cost competition persists, no premium positioning. |
| Moderate | $6.00 - $8.00 | Introduction of enhanced formulations, brand positioning. |
| Aggressive | $8.00 - $10.00 | Premium product with differentiated delivery or organic ingredients. |
Volume and Revenue Estimates
Assuming market penetration of 10% in the pediatric fever/pain segment by year 3:
| Year | Estimated Market Volume (units) | Revenue (USD) at median price | Growth Rate |
|---|---|---|---|
| 2023 | 200 million units | $900 million | — |
| 2024 | 220 million units | $1.04 billion | 15% |
| 2025 | 240 million units | $1.20 billion | 15% |
Key Factors Influencing Price
- Regulatory approval timelines: Delays can impact entry and pricing.
- Brand recognition: Established brands command higher prices.
- Manufacturing costs: Scale and sourcing influence margins.
- Competitive responses: Pricing adjustments to counter new entrants.
Regulatory and Policy Drivers
- Stringent safety regulations restrict marketing and formulation modifications.
- Pediatric use labeling impacts reimbursement and coverage.
- Increasing push for organic and dye-free formulations can shift price points upward.
Summary
The pediatric pain and fever market is mature, with dominant brands and a predictable pricing landscape. New product entrants like SM CHLD PAIN-FEVER will target market share growth through differentiation, effective regulatory navigation, and strategic pricing. Price range projections over five years vary from USD 4.50 to USD 10.00 per unit, contingent on formulation innovation and positioning.
Key Takeaways
- The pediatric analgesic market is stable with steady growth.
- Entry barriers include regulatory clearance and established brand loyalty.
- Price projections depend on product differentiation, with potential for premium positioning.
- Volume growth hinges on effective distribution and marketing.
- Regulatory and policy changes can alter pricing and market share dynamics.
FAQs
1. What are the main competitors for SM CHLD PAIN-FEVER?
Tylenol, Children's Motrin, and store-brand pediatric formulations are the primary competitors.
2. How does regulatory approval impact market entry?
Regulatory approval can delay launch timelines; however, pediatric-specific data can support premium pricing.
3. What factors could influence the pricing of SM CHLD PAIN-FEVER?
Formulation innovation, regulatory requirements, manufacturing costs, and competitive pricing strategies.
4. What is the typical profit margin for pediatric analgesic medications?
Profit margins range from 20% to 40%, depending on manufacturing costs and market positioning.
5. How might policy changes affect this market?
Policies favoring organic, dye-free, or preservative-free formulations could shift demand and pricing upward.
Sources
[1] MarketResearch.com. (2022). Pediatric Pain Management Market Size and Trends.
[2] Grand View Research. (2023). Pediatric Analgesics Market Analysis.
[3] U.S. Food and Drug Administration. (2023). Pediatric Drug Approvals and Guidelines.
[4] European Medicines Agency. (2023). Pediatric Medicines Regulation.
[5] Smith, J. (2021). Pediatric analgesics: Market dynamics and future outlook. Journal of Pharmacology.
More… ↓
